Efficacy, Safety, and Tolerability of Sertraline in Patients with Late-Life Depression and Comorbid Medical Illness

Javaid Sheikh, Erin L. Cassidy, P. Murali Doraiswamy, Ronald M. Salomon, Mady Hornig, Peter J. Holland, Francine S. Mandel, Cathryn M. Clary, Tal Burt

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

OBJECTIVES: To report on the efficacy, safety, and tolerability of sertraline in the treatment of elderly depressed patients with and without comorbid medical illness. SETTING: Multicenter. DESIGN: Randomized, double-blind, placebo-controlled study. PARTICIPANTS: A total of 752 patients aged 60 and older with diagnosis of major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis. MEASUREMENTS: Outcome measures included the 17-item Hamilton Depression Scale (HAMD); the Clinical Global Depression-Severity/Improvement Severity/Improvement (CGI-S/CGI-I); efficacy and safety/adverse event assessments; Quality of Life, Enjoyment, and Satisfaction Questionnaire; and the Medical Outcomes Study 36-Item Short-Form Health Status Survey. RESULTS: In the overall sample, sertraline was superior to placebo on all three primary outcome measures, HAMD, and overall clinical severity and change (CGI-S/CGI-I). Furthermore, therapeutic response to sertraline was comparable in those with or without medical comorbidity, and there were no treatment-by-comorbidity group interactions. Sertraline was also associated with a faster time to response than placebo in the comorbid group (P < .006). Sertraline-treated patients in the comorbid group had similar adverse events and discontinuations when compared to those in the noncomorbid group. CONCLUSION: Sertraline was efficacious in reducing depressive symptomatology, regardless of the presence of comorbid medical illness. Sertraline was safe and well tolerated by patients with or without medical illness.

Original languageEnglish
Pages (from-to)86-92
Number of pages7
JournalJournal of the American Geriatrics Society
Volume52
Issue number1
DOIs
Publication statusPublished - Jan 2004
Externally publishedYes

Fingerprint

Sertraline
Depression
Safety
Placebos
Outcome Assessment (Health Care)
Comorbidity
Major Depressive Disorder
Health Surveys
Diagnostic and Statistical Manual of Mental Disorders
Health Status
Therapeutics
Quality of Life

Keywords

  • Comorbid illness
  • Depression
  • Late-life

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Efficacy, Safety, and Tolerability of Sertraline in Patients with Late-Life Depression and Comorbid Medical Illness. / Sheikh, Javaid; Cassidy, Erin L.; Doraiswamy, P. Murali; Salomon, Ronald M.; Hornig, Mady; Holland, Peter J.; Mandel, Francine S.; Clary, Cathryn M.; Burt, Tal.

In: Journal of the American Geriatrics Society, Vol. 52, No. 1, 01.2004, p. 86-92.

Research output: Contribution to journalArticle

Sheikh, Javaid ; Cassidy, Erin L. ; Doraiswamy, P. Murali ; Salomon, Ronald M. ; Hornig, Mady ; Holland, Peter J. ; Mandel, Francine S. ; Clary, Cathryn M. ; Burt, Tal. / Efficacy, Safety, and Tolerability of Sertraline in Patients with Late-Life Depression and Comorbid Medical Illness. In: Journal of the American Geriatrics Society. 2004 ; Vol. 52, No. 1. pp. 86-92.
@article{947c6e6060d24de8a20e96f444dff680,
title = "Efficacy, Safety, and Tolerability of Sertraline in Patients with Late-Life Depression and Comorbid Medical Illness",
abstract = "OBJECTIVES: To report on the efficacy, safety, and tolerability of sertraline in the treatment of elderly depressed patients with and without comorbid medical illness. SETTING: Multicenter. DESIGN: Randomized, double-blind, placebo-controlled study. PARTICIPANTS: A total of 752 patients aged 60 and older with diagnosis of major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis. MEASUREMENTS: Outcome measures included the 17-item Hamilton Depression Scale (HAMD); the Clinical Global Depression-Severity/Improvement Severity/Improvement (CGI-S/CGI-I); efficacy and safety/adverse event assessments; Quality of Life, Enjoyment, and Satisfaction Questionnaire; and the Medical Outcomes Study 36-Item Short-Form Health Status Survey. RESULTS: In the overall sample, sertraline was superior to placebo on all three primary outcome measures, HAMD, and overall clinical severity and change (CGI-S/CGI-I). Furthermore, therapeutic response to sertraline was comparable in those with or without medical comorbidity, and there were no treatment-by-comorbidity group interactions. Sertraline was also associated with a faster time to response than placebo in the comorbid group (P < .006). Sertraline-treated patients in the comorbid group had similar adverse events and discontinuations when compared to those in the noncomorbid group. CONCLUSION: Sertraline was efficacious in reducing depressive symptomatology, regardless of the presence of comorbid medical illness. Sertraline was safe and well tolerated by patients with or without medical illness.",
keywords = "Comorbid illness, Depression, Late-life",
author = "Javaid Sheikh and Cassidy, {Erin L.} and Doraiswamy, {P. Murali} and Salomon, {Ronald M.} and Mady Hornig and Holland, {Peter J.} and Mandel, {Francine S.} and Clary, {Cathryn M.} and Tal Burt",
year = "2004",
month = "1",
doi = "10.1111/j.1532-5415.2004.52015.x",
language = "English",
volume = "52",
pages = "86--92",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Efficacy, Safety, and Tolerability of Sertraline in Patients with Late-Life Depression and Comorbid Medical Illness

AU - Sheikh, Javaid

AU - Cassidy, Erin L.

AU - Doraiswamy, P. Murali

AU - Salomon, Ronald M.

AU - Hornig, Mady

AU - Holland, Peter J.

AU - Mandel, Francine S.

AU - Clary, Cathryn M.

AU - Burt, Tal

PY - 2004/1

Y1 - 2004/1

N2 - OBJECTIVES: To report on the efficacy, safety, and tolerability of sertraline in the treatment of elderly depressed patients with and without comorbid medical illness. SETTING: Multicenter. DESIGN: Randomized, double-blind, placebo-controlled study. PARTICIPANTS: A total of 752 patients aged 60 and older with diagnosis of major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis. MEASUREMENTS: Outcome measures included the 17-item Hamilton Depression Scale (HAMD); the Clinical Global Depression-Severity/Improvement Severity/Improvement (CGI-S/CGI-I); efficacy and safety/adverse event assessments; Quality of Life, Enjoyment, and Satisfaction Questionnaire; and the Medical Outcomes Study 36-Item Short-Form Health Status Survey. RESULTS: In the overall sample, sertraline was superior to placebo on all three primary outcome measures, HAMD, and overall clinical severity and change (CGI-S/CGI-I). Furthermore, therapeutic response to sertraline was comparable in those with or without medical comorbidity, and there were no treatment-by-comorbidity group interactions. Sertraline was also associated with a faster time to response than placebo in the comorbid group (P < .006). Sertraline-treated patients in the comorbid group had similar adverse events and discontinuations when compared to those in the noncomorbid group. CONCLUSION: Sertraline was efficacious in reducing depressive symptomatology, regardless of the presence of comorbid medical illness. Sertraline was safe and well tolerated by patients with or without medical illness.

AB - OBJECTIVES: To report on the efficacy, safety, and tolerability of sertraline in the treatment of elderly depressed patients with and without comorbid medical illness. SETTING: Multicenter. DESIGN: Randomized, double-blind, placebo-controlled study. PARTICIPANTS: A total of 752 patients aged 60 and older with diagnosis of major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis. MEASUREMENTS: Outcome measures included the 17-item Hamilton Depression Scale (HAMD); the Clinical Global Depression-Severity/Improvement Severity/Improvement (CGI-S/CGI-I); efficacy and safety/adverse event assessments; Quality of Life, Enjoyment, and Satisfaction Questionnaire; and the Medical Outcomes Study 36-Item Short-Form Health Status Survey. RESULTS: In the overall sample, sertraline was superior to placebo on all three primary outcome measures, HAMD, and overall clinical severity and change (CGI-S/CGI-I). Furthermore, therapeutic response to sertraline was comparable in those with or without medical comorbidity, and there were no treatment-by-comorbidity group interactions. Sertraline was also associated with a faster time to response than placebo in the comorbid group (P < .006). Sertraline-treated patients in the comorbid group had similar adverse events and discontinuations when compared to those in the noncomorbid group. CONCLUSION: Sertraline was efficacious in reducing depressive symptomatology, regardless of the presence of comorbid medical illness. Sertraline was safe and well tolerated by patients with or without medical illness.

KW - Comorbid illness

KW - Depression

KW - Late-life

UR - http://www.scopus.com/inward/record.url?scp=0346499168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346499168&partnerID=8YFLogxK

U2 - 10.1111/j.1532-5415.2004.52015.x

DO - 10.1111/j.1532-5415.2004.52015.x

M3 - Article

VL - 52

SP - 86

EP - 92

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 1

ER -